Evidence map›Paper›PMID 42043684›Full record

ArticleEndocrine2026

Adverse Events Associated with Growth Hormone Therapy: A Pharmacovigilance Study.

Xie Zhanfang, Hu Yan, Wang Yanhong, Luo Liujin, Li Ganggang, Zhou Jing

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xie ZhanfangDepartment of Pharmacy, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID http://orcid.org/0000-0003-0606-2184
Hu YanDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China.ORCID http://orcid.org/0000-0003-0788-8308
Wang YanhongDepartment of Pharmacy, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Luo LiujinDepartment of Pharmacy, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Li GanggangDepartment of Pharmacy, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. liggzdwfy@163.com.ORCID http://orcid.org/0000-0002-2357-9866
Zhou JingDepartment of Pharmacy, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. zhoujing@gdph.org.cn.ORCID http://orcid.org/0000-0002-0971-1867

Funding

Jointly Co-built Project of the 2025 Henan Provincial Medical Science and Technology Research Program LHGJ20250406Key Research and Development and Promotion Special Projects of Henan Province No.242102311279Special Project for Traditional Chinese Medicine Research of Henan Province NO.2025ZY3149Youth Cultivation Plan Project of the Fifth Affiliated Hospital of Zhengzhou University in 2025 NO.YQ2024016
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse eventsFAERSgrowth hormonepharmacovigilance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.